Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 3/20 | 1.00 |
| ▸ | MAX | P61244 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | IGF1R | P08069 | 1/20 | 0.77 |
| ▸ | PIM1 | P11309 | 1/20 | 0.77 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.77 |
| ▸ | CRHBP | P24387 | 2/20 | 0.68 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.68 |
| ▸ | NAT1 | P18440 | 5/20 | 0.66 |
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.66 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.65 |
| ▸ | CLK1 | P49759 | 1/20 | 0.65 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.65 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.65 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346693 | 1.00 | MYC (1.00) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL346694 | 1.00 | MYC (1.00) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL4051343 | 0.89 | NPC1 (0.79) | MYCMAXNPC1RAB9ACISD1 | |
| SCHEMBL4051348 | 0.89 | NPC1 (0.79) | MYCMAXNPC1RAB9ACISD1 | |
| SCHEMBL2539569 | 0.87 | PIM1 (1.00) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL2539566 | 0.87 | PIM1 (1.00) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL2539573 | 0.87 | PIM1 (1.00) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL27412991 | 0.85 | MYC (0.74) | MYCMAXNPC1RAB9ACRHBP | |
| SCHEMBL8172749 | 0.84 | MYC (0.73) | MYCMAXNPC1RAB9AIGF1R | |
| SCHEMBL8172752 | 0.84 | MYC (0.73) | MYCMAXNPC1RAB9AIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119424641-A | New application of RTKs/RAS/RAF/c-Myc signal channel inhibitor | 哈尔滨工业大学 | 2025-02-14 | — | — | CN | claimed |
| US-20240360417-A1 | CELL THERAPEUTIC AGENT FOR CANCER TREATMENT AND COMBINATION THERAPY WITH SAME | CELL&BRAIN CO LTD (KR) | 2024-10-31 | — | — | US | claimed |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-09-10 | — | — | US | claimed |
| CN-118512443-A | Application of compound 10058-F4 in preparation of medicine for preventing and treating pseudorabies virus infection | 浙江农林大学 | 2024-08-20 | — | — | CN | claimed |
| US-20240000935-A1 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2024-01-04 | — | — | US | claimed |
| EP-4251177-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | Geneius Biotechnology, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| WO-2022115641-A2 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | GENEIUS BIOTECHNOLOGY, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| US-20220111044-A1 | WHOLE CELL TUMOR VACCINES AND METHODS OF USE THEROF | CHILDREN'S NATIONAL MEDICAL CENTER | 2022-04-14 | — | — | US | claimed |
| WO-2013163454-A2 | PSYLLID ATTRACTANTS AND THEIR USES | INSCENT, INC. (US) | 2013-10-31 | — | — | WO | claimed |
| US-12630883-B2 | Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260132471-A1 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | FOUNDATION MEDICINE, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4740951-A2 | IGH REARRANGEMENTS AND USES THEREOF | Foundation Medicine, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-04-23 | — | — | US | disclosed |
| US-12605374-B2 | Methods for drug screening and compositions useful for the inhibition of cell proliferation and/or cell survival | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| WO-2013163454-A2 | PSYLLID ATTRACTANTS AND THEIR USES | INSCENT, INC. (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130287727-A1 | Psyllid Attractants and Their Uses | INSCENT, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130287727-A1 | Psyllid Attractants and Their Uses | INSCENT, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| US-20130287727-A1 | Psyllid Attractants and Their Uses | INSCENT, INC. (US) | 2013-10-31 | — | — | US | disclosed |
| WO-2013152193-A2 | METHODS OF TREATING PROLIFERATIVE DISORDERS WITH MALATE OR DERIVATIVES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20120015989-A1 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605374-B2 | Methods for drug screening and compositions useful for the inhibition of cell proliferation and/or cell survival | MKI67, DUSP10, MCL1 | MYC 2960/4885MAX 3759/4885NPC1 474/4885 |
| US-20260108514-A1 | METHOD OF INHIBITING EPITHELIAL-MESENCHYMAL TRANSITION AND CANCER METASTASIS | HDAC5, HDAC6, GSK3B | MYC 1085/4885MAX 3010/4885NPC1 1646/4885 |
| US-20130287727-A1 | Psyllid Attractants and Their Uses | L3MBTL3, LPAR3, LPXN | MYC 1550/4885MAX 1867/4885NPC1 3023/4885 |
| US-20120015989-A1 | LINKED MYC-MAX SMALL MOLECULE INHIBITORS | MYC, MAX, MYCBP | MYC 1/4885MAX 2/4885NPC1 2586/4885 |
| US-12630883-B2 | Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes | BCL3, BRD4, BCL6 | MYC 25/4885MAX 3679/4885NPC1 3009/4885 |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | CD44, PGF, SLC46A1 | MYC 2759/4885MAX 4299/4885NPC1 781/4885 |
| US-20260132471-A1 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | MSH2, MSH6, PMS2 | MYC 322/4885MAX 1985/4885NPC1 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.